Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence SSKITHRIHWESASLL
Primary information
sequence IDSeq_7646
Peptide sequenceSSKITHRIHWESASLL
CancerPDF_ID CancerPDF_ID31, CancerPDF_ID197, CancerPDF_ID209, CancerPDF_ID924, CancerPDF_ID1047, CancerPDF_ID1471, CancerPDF_ID2707, CancerPDF_ID9478, CancerPDF_ID12274, CancerPDF_ID12708,
PMID16896061,19728888,19728888,19795908,16395409,21136997,21136997,26379225,26992070,27058005
Protein NameComplement C3f,Complement C3f,Complement C3 f,Complement C3,Complement C3f,Complement C3,Complement C3,Complement C3,Complement C3,Complement C3
UniprotKB Entry NameCO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN,CO3_HUMAN
FluidSerum,Serum,Serum,Plasma,Serum,Serum,Plasma,Plasma,Serum,Serum
M/Z1864.95,1865.0022,1865.0022,933.05,1864.95,1863.99553,1863.9955,1865,1863.9955,1865.05
Charge1,NA,NA,2,1,1,1,NA,NA,NA
Mass (in Da)1864.99,NA,NA,NA,NA,NA,NA,NA,1864.997837,NA
fdrNA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Profiling TechniqueMALDI-TOF,MALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,LC-MS,MALDI-TOF
Peptide Identification techniqueQ/TOF MS/MS,LC-MS/MS,LC-MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,MALDI-TOF/TOF,LC-MS/MS,LC-MS/MS
Quantification TechniqueNA,NA,NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,NA,NA,NA
Labelled/Label FreeLabel Free,Label Free,Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free
FDRNA,NA,NA,less than 7%,less than 1 “5,NA,NA,NA,FDR 1 %,NA
CancerPDF_ID CancerPDF_ID31, CancerPDF_ID197, CancerPDF_ID209, CancerPDF_ID924, CancerPDF_ID1047, CancerPDF_ID1471, CancerPDF_ID2707, CancerPDF_ID9478, CancerPDF_ID12274, CancerPDF_ID12708,
p-Value1.00E-05,less than 0.05,2.83E-05,NA,1.85E-15,NA,NA,NA,NA,"less than 0.001,less than 0.05,0.090"
SoftwareMASCOT,MASCOT(v 2.0.04 for Windows),MASCOT(v 2.0.04 for Windows),FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT (v 2.3),SEQUEST and Maxquant,Proteome Discoverer
Length16,16,16,16,16,16,16,16,16,16
Cancer TypeMetastatic thyroid carcinomas,"Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy","Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy",Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,Colorectal cancer,Melanoma,Breast cancer
DatabaseNCBI refseq Protein Database,SwissProt Database (release 54.7),SwissProt Database (release 54.7),NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,UniprotKB,SwissProt Database,SwissProt Database
ModificationNA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"11 NSCLC patients with the shortest PFS, 11 patients with the longest PFS","27 patients, 13 normal individuals","42 normal, 28 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,27 healthy individuals,"94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative",8 cancer samples and 4 healthy samples," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)."
RegulationDifferentially expressed between cancer vs normal samples,Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS,Differentially expressed between NSCLC patients vs healthy volunteers,NA,"For Prostate & bladder (Higher) and for breast (Lower) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =2.18, 3.33 and 0.3 in prostate, bladder and breast cancer respectively",NA,NA,Similar intensity into the case groups.,"Present in 6 cancer samples out of 8 cancer samples. ,Present in 1 healthy samples out of 4 healthy samples.","Upregulated with the fold change of 2.06 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.35, Upregulated in BC vs healthy with 1.344 fold change"
ValidationIndependent validation,Independent validation,Independent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,NA,na,NA
Sensitivity95% on independent dataset,1,1,NA,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,NA,NA,NA,NA,NA
Specificity95% on independent dataset,0.73,0.96,NA,NA,NA,NA,NA,NA,NA
AccuracyNA,0.86,0.98,NA,97.5 % on validation dataset,NA,NA,NA,NA,NA
Peptide AtlasNA
IEDB533899